ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the ...
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related ...
27don MSN
MaxCyte outlines $30M-$32M 2026 revenue outlook as board authorizes $10M share repurchase program
Q1 2026 Management view “MaxCyte reported $9.7 million of total revenue, including $6.2 million of core revenue and $3.4 million of SPL program-related revenue, which consists of milestones and ...
Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks MaxCyte ( (MXCT)) has provided an ...
MaxCyte (NASDAQ:MXCT) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement. Analysts anticipate MaxCyte to report an ...
ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance ...
MaxCyte Inc MXCT shares plummeted after the company released preliminary Q3 revenue of $7.8 million – 8.0 million, a Y/Y decrease of 25 -27%, due to continued reduced customer activity in the sector.
ROCKVILLE, MD—On a brisk, sun-splashed midweek morning in the suburbs of Washington DC, the staff at MaxCyte have double reason to celebrate. Every Wednesday, they are treated to free lunch in the ...
GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte, Inc., the pioneer in scalable, high performance cell transfection systems, is hosting a series of events at Cambridge Health Institute’s BioProcessing ...
GAITHERSBURG, Md., Sept. 9, 2020 /PRNewswire/ -- MaxCyte, Inc., a global cell-based therapies and life sciences company, announced today that Amanda L. Murphy, CFA, has joined the Company as Chief ...
FLORHAM PARK, N.J. and GAITHERSBURG, Md., May 25, 2021 /PRNewswire/ — Celularity, Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results